Crucially, the potent antitumour activity displayed by IL-2WTFc was also dependent on these two properties, with mutation of either the CD25- or FcγR-binding sites resulting in reduced treatment efficacy in the B16F10 melanoma and CT26 colorectal carcinoma models. This evidence concerns the gene FCGR2A and colorectal carcinoma.